Search tips
Search criteria 


Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 1998 July; 106(7): 393–400.
PMCID: PMC1533137
Research Article

A physiologically based pharmacokinetic model for 2,4-toluenediamine leached from polyurethane foam-covered breast implants.


Physiologically based pharmacokinetic (PBPK) modeling was used to assess the low-dose exposure of patients to the carcinogen 2, 4-toluenediamine (2,4-TDA) released from the degradation of the polyester urethane foam (PU) used in Meme silicone breast implants. The tissues are represented as five compartments: liver, kidney, gastrointestinal tract, slowly perfused tissues (e.g., fat), and richly perfused tissues (e.g., muscle). The PBPK model was fitted to the plasma and urine concentrations of 2,4-TDA and its metabolite 4-AAT (4-N-acetyl-2-amino toluene) in rats given low doses of 2, 4-TDA intravenously and subcutaneously. The rat model was extrapolated to simulate oral and implant routes in rats. After adjusting for human physiological parameters, the model was then used to predict the bioavailability of 2,4-TDA released from a typical 4.87-g polyester urethane foam implant found in a patient who weighed 58 kg with the Meme and had the breast implant for 10 years. A quantitative risk assessment for 2,4-TDA was performed and the polyester urethane foam did present an unreasonable risk to health for the patient.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (3.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Picha GJ, Goldstein JA, Stohr E. Natural-Y Même polyurethane versus smooth silicone: analysis of the soft-tissue interaction from 3 days to 1 year in the rat animal model. Plast Reconstr Surg. 1990 Jun;85(6):903–916. [PubMed]
  • Smahel J. Tissue reactions to breast implants coated with polyurethane. Plast Reconstr Surg. 1978 Jan;61(1):80–85. [PubMed]
  • Melmed EP. Polyurethane implants: a 6-year review of 416 patients. Plast Reconstr Surg. 1988 Aug;82(2):285–290. [PubMed]
  • Amin P, Wille J, Shah K, Kydonieus A. Analysis of the extractive and hydrolytic behavior of microthane poly(ester-urethane) foam by high pressure liquid chromatography. J Biomed Mater Res. 1993 May;27(5):655–666. [PubMed]
  • Batich C, Williams J, King R. Toxic hydrolysis product from a biodegradable foam implant. J Biomed Mater Res. 1989 Dec;23(A3):311–319. [PubMed]
  • Benoit FM. Degradation of polyurethane foams used in the Même breast implant. J Biomed Mater Res. 1993 Oct;27(10):1341–1348. [PubMed]
  • Glinsukon T, Benjamin T, Grantham PH, Weisburger EK, Roller PP. Enzymic N-acetylation of 2,4-toluenediamine by liver cytosols from various species. Xenobiotica. 1975 Aug;5(8):475–483. [PubMed]
  • Grantham PH, Mohan L, Benjamin T, Roller PP, Miller JR, Weisburger EK. Comparison of the metabolism of 2,4-toluenediamine in rats and mice. J Environ Pathol Toxicol. 1979 Dec;3(1-2):149–166. [PubMed]
  • Waring RH, Pheasant AE. Some phenolic metabolites of 2, 4-diaminotoluene in the rabbit, rat and guinea-pig. Xenobiotica. 1976 Apr;6(4):257–262. [PubMed]
  • Weisburger EK, Russfield AB, Homburger F, Weisburger JH, Boger E, Van Dongen CG, Chu KC. Testing of twenty-one environmental aromatic amines or derivatives for long-term toxicity or carcinogenicity. J Environ Pathol Toxicol. 1978 Nov-Dec;2(2):325–356. [PubMed]
  • Ito N, Hiasa Y, Konishi Y, Marugami M. The development of carcinoma in liver of rats treated with m-toluylenediamine and the synergistic and antagonistic effects with other chemicals. Cancer Res. 1969 May;29(5):1137–1145. [PubMed]
  • Timchalk C, Smith FA, Bartels MJ. Route-dependent comparative metabolism of [14C]toluene 2,4-diisocyanate and [14C]toluene 2,4-diamine in Fischer 344 rats. Toxicol Appl Pharmacol. 1994 Feb;124(2):181–190. [PubMed]
  • Chan SC, Birdsell DC, Gradeen CY. Detection of toluenediamines in the urine of a patient with polyurethane-covered breast implants. Clin Chem. 1991 May;37(5):756–758. [PubMed]
  • Chan SC, Birdsell DC, Gradeen CY. Urinary excretion of free toluenediamines in a patient with polyurethane-covered breast implants. Clin Chem. 1991 Dec;37(12):2143–2145. [PubMed]
  • Sepai O, Henschler D, Czech S, Eckert P, Sabbioni G. Exposure to toluenediamines from polyurethane-covered breast implants. Toxicol Lett. 1995 May;77(1-3):371–378. [PubMed]
  • Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997 Jul-Aug;13(4):407–484. [PubMed]
  • Ramsey JC, Andersen ME. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol. 1984 Mar 30;73(1):159–175. [PubMed]
  • Andersen ME, Clewell HJ, 3rd, Gargas ML, Smith FA, Reitz RH. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol. 1987 Feb;87(2):185–205. [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science